RecruitingPhase 1/2

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

United States, Puerto Rico242 participantsStarted 2018-06-08

Plain-language summary

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Head and Neck Cancers ("HNC") (of any types),
. Esophageal cancer,
. Lung cancers (of any types),
. Mesothelioma,
. Pancreatic cancers,
. TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers; or,
. any NTRK1+ solid tumors or lymphoma\*, that is R/R/I to SOC.
. Absolute neutrophil count ≥1.5x10\^9/L

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number and severity of treatment-emergent Adverse Events (Phase 1)

Timeframe: First cycle (21 days per cycle)

To determine the recommended Phase 2 dose for VMD-928 (Phase 1)

Timeframe: First cycle (21 days per cycle)

To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)

Timeframe: First cycle (21 days per cycle)

Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)

Timeframe: Up to 18 months

Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)

Timeframe: Up to 18 months

Trial details

NCT IDNCT03556228

SponsorVM Oncology, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-12

Contact for this trial

Jay Wu, PhD

1-510-270-2790 OM@VMOncology.com

View on ClinicalTrials.gov More Head and Neck Carcinoma trials

Plain-language summary

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Head and Neck Cancers ("HNC") (of any types),
. Esophageal cancer,
. Lung cancers (of any types),
. Mesothelioma,
. Pancreatic cancers,
. TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers; or,
. any NTRK1+ solid tumors or lymphoma\*, that is R/R/I to SOC.
. Absolute neutrophil count ≥1.5x10\^9/L

What they're measuring

Number and severity of treatment-emergent Adverse Events (Phase 1)

Timeframe: First cycle (21 days per cycle)

To determine the recommended Phase 2 dose for VMD-928 (Phase 1)

Timeframe: First cycle (21 days per cycle)

To determine the RP2D of VMD-928 in combination with pembrolizumab (Phase 1)

Timeframe: First cycle (21 days per cycle)

Antitumor activity of VMD-928 in subjects with TrkA-driven tumors (Phase 2)

Timeframe: Up to 18 months

Antitumor activity of VMD-928 in combination with pembrolizumab in subjects with TrkA-driven tumors (Phase 2)

Timeframe: Up to 18 months